The World Needs New Antibiotics. The Market Guarantees No One Will Make Them.
Resistant infections kill over a million people a year and rising, yet the companies that make new antibiotics keep going bankrupt. A bipartisan bill and a live UK model could rewire the economics overnight — here's who collects.
There is a drug that costs more than $1 billion to bring to market, takes a decade to develop, and — if it works exactly as designed — you are supposed to use as little as possible. That is the business of making a new antibiotic. It is the only corner of the pharmaceutical industry where commercial success and public health point in opposite directions, and the market has responded to that contradiction the way markets always do: it has walked away.
The numbers describing the disease are staggering, and they are getting worse. In 2021, drug-resistant bacterial infections were directly responsible for roughly 1.14 million deaths worldwide and contributed to nearly 5 million. The first long-range global analysis, published in The Lancet in 2024, projected that antimicrobial resistance will directly cause more than 39 million deaths between 2025 and 2050 — about three deaths every minute — with annual direct deaths climbing 67.5% to 1.91 million by mid-century. In the United States alone, resistant infections already sicken more than 2.8 million people a year and kill over 35,000.
That is the demand side of a market. It is enormous, it is inelastic, and it is growing. And yet the supply side is collapsing.
The most broken market in medicine
Antibiotics break the fundamental logic of pharmaceutical investing. A cancer drug or a GLP-1 obesity therapy generates more revenue the more it is prescribed. A new antibiotic is the reverse: the moment it launches, hospitals lock it in a drawer and label it "reserve," to be used only when everything older has failed. Good medicine — antibiotic stewardship — is deliberately designed to suppress the product's sales. The better the drug, the less it is used.
Investors learned exactly what that means the hard way. Achaogen won FDA approval for Zemdri, a new antibiotic for drug-resistant infections, in 2018 — and filed for bankruptcy less than a year later, after the drug booked roughly $800,000 in sales. Melinta Therapeutics, which billed itself as the largest pure-play antibiotics company in the world, filed for Chapter 11 in December 2019. Aradigm filed the same year. The rule of thumb in the industry is that a new antibiotic needs to clear about $300 million in annual sales to be viable; almost none of the recent launches come anywhere close.
The big players read the same spreadsheet and left. AstraZeneca, Novartis, and Sanofi have all exited antibiotic R&D. What remains is a handful of small-cap developers surviving on grants, and a pipeline the World Health Organization has repeatedly called insufficient against the pathogens it considers most dangerous.
Briefings like this land in members' inboxes before the market prices them in. Join free →
Why this is a policy story before it is a stock story
Everyone who has studied the problem agrees on the diagnosis, and — unusually — on the cure. If the market cannot reward a new antibiotic through sales volume, then you have to pay for it another way: decouple the payment from the prescription entirely. Pay a developer a large, fixed sum for access to a working drug, the way a government pays for a strategic reserve or a fire department it hopes never to use. Economists call it a "pull incentive." Policy people call it a delinked subscription model. It is the single most-endorsed idea in the field.
The United States has a bill to do exactly that. And in 2026, for the fourth time, Congress is trying to pass it.
The question every investor in this corner of biotech is really asking is narrower and more urgent than the death statistics suggest: is this the year the economics finally change — and if so, which of the surviving companies is positioned to collect?
The rest of this briefing is for paid members: the exact mechanics and dollar figures in the 2026 PASTEUR Act, its real odds in this Congress, the shortlist of surviving public antibiotic developers and where each one sits, the parallel UK model that's already paying out, and the bottom-line positioning framework for a catalyst most healthcare funds aren't watching.
AlphaBriefing Paid gets you every investment thesis, scenario framework, and catalyst brief we publish — the analysis private intel clients pay four figures for, at a fraction of that.